About 200 reports

  • BREAST CANCER: OVERVIEW
  • TREATMENT REGIMEN FOR BREAST CANCER

About Breast Cancer mAbs Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates...

  • Breast Cancer
  • Amgen Inc.
  • Biocon Limited
  • Mylan Inc.
  • Roche Group
  • 1.1 BREAST CANCER
  • BREAST CANCER BY TYPES

‘Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also...

  • Breast Cancer
  • World
  • Market Size
  • AbbVie Inc.
  • AstraZeneca PLC
  • BREAST CANCER
  • BREAST CANCER

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established...

  • Breast Cancer
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • MOLECULAR SUBTYPES OF BREAST CANCER
  • PROGNOSIS FOR BREAST CANCER

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer...

  • Breast Cancer
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • BREAST CANCER NETWORK AUSTRALIA
  • NATIONAL BREAST CANCER FOUNDATION

Get 10% Free Customization in this Report Breast Cancer Screening Market is expected to be more than US$ 20 Billion by 2022. Breast cancer is the 2nd most common cancer among the women in the world. Number of breast cancer cases in less developed regions is higher than developed regions. Breast cancer mammography screening population...

  • Breast Cancer
  • Magnetic Resonance Imaging
  • Southeast Asia
  • Western Europe
  • Forecast
  • HER2-NEGATIVE BREAST CANCER MARKET IN AMERICAS 2014-2019 ($ MILLIONS)
  • HER2-NEGATIVE BREAST CANCER MARKET IN APAC 2014-2019 ($ MILLIONS)

About HER2-negative breast cancer HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients...

  • Breast Cancer
  • Alcon, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • NATIONAL BREAST CANCER FOUNDATION
  • BREAST CANCER NETWORK AUSTRALIA

Breast cancer is one of the major cause of mortality among women in both the developed and developing world. Early detection remains the primary defense available to patients in preventing the development of life-threatening breast cancer. Breast cancer screening is the regular examination of a woman's breasts to find breast cancer early....

  • Breast Cancer
  • Eastern Europe
  • Northern Europe
  • Western Europe
  • Forecast
  • Breast Cancer Therapeutics Market, Competitor Matrix for Breast Cancer Marketed and Pipeline
  • Breast Cancer Therapeutics Market, Southeast Asia, Pembrolizumab, Market

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market Summary Breast cancer is a malignant neoplasm that begins in the breast tissue, which is made up of glands for milk production called lobules and the ducts that connect the lobules...

  • Breast Cancer
  • Southeast Asia
  • World
  • Market Size
  • Novartis AG
  • 6.2.1 BREAST CANCER TEST MARKET
  • China - Forecast for Breast Cancer Test Market (Million US$), 2017 - 2022

China molecular diagnostics market is expected to be more than USD 1.5 Billion by the year 2022. As a part of the evolution of medicine in China; en route for targeted therapy and recognizing the revenue as well as profits in this new market, Diagnostics instruments are the foundation of the biotechnology industry and the pharmaceutical industry...

  • Breast Cancer
  • Cancer
  • China
  • East Asia
  • OriGene Technologies, Inc.
  • 13.Breast Cancer Screening Market Growth Drivers
  • 8.1 Singapore Breast Cancer Mammography Screening Population &

Get 10% Free Customization in this Report Asia breast cancer screening market size is expected to cross over US$ 4 Billion by 2022. China, Japan and Korea are the top most contributors. Increasing breast cancer awareness, government and NGOs support breast cancer screening programs and ageing women population are major driving...

  • Breast Cancer
  • Asia
  • East Asia
  • Southeast Asia
  • Forecast
  • BREAST CANCER NETWORK AUSTRALIA
  • NATIONAL BREAST CANCER FOUNDATION

Breast cancer is one of the major cause of mortality among women in both the developed and developing world. Early detection remains the primary defense available to patients in preventing the development of life-threatening breast cancer. Breast cancer screening is the regular examination of a woman's breasts to find breast cancer early....

  • Breast Cancer
  • Eastern Europe
  • Northern Europe
  • Western Europe
  • Forecast
  • 14.2 Increasing Breast Cancer Cases
  • 14.Europe Breast Cancer Screening Market - Growth

Europe Breast Cancer Screening Market will be less than US$ 8 Billion by the end of year 2022. Breast cancer is one of the most dangerous diseases in the Europe region. Its incidence rate in Europe was 92.9 women per 100,000 women and mortality rate was 23.1 per 100,000 women. So, most of the countries of Europe has adopted or in the process...

  • Breast Cancer
  • Europe
  • Western Europe
  • World
  • Forecast
  • Risk Factors and Comorbidities for Breast Cancer
  • 2.6.1 Diagnosed Incident Cases of Invasive Breast Cancer

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025 Summary Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream...

  • Breast Cancer
  • China
  • Japan
  • United States
  • Forecast

Global Breast Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Breast Cancer
  • France
  • United States
  • World
  • Forecast
  • Global HER-2 Positive Breast Cancer Market
  • Global HER-2 Positive Breast Cancer Market

About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated...

  • Breast Cancer
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Inc.
  • Breast Cancer Therapeutics Market, Global, Heat Map
  • 7.1.1 INCREASED UPTAKE OF TARGETED AND COMBINATION THERAPIES FOR BREAST CANCER

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence Summary Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making...

  • Breast Cancer
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

Global Breast Cancer Predictive Genetic Testing Market Outlook 2022 ##.

  • Breast Cancer
  • Cancer
  • Pathology
  • World
  • Breast Cancer Therapeutics, US, Age-Specific Incidence Rates of Breast Cancer
  • Breast Cancer Therapeutics Market, Global, Number of Disclosed and

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence Summary Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the...

  • Breast Cancer
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

Breast Cancer Phase ## Clinical Trials, 2016 ##.

  • Breast Cancer
  • France
  • Germany
  • United States
  • Market Size

Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022 ##.

  • Breast Cancer
  • Therapy
  • Vaccine
  • World
  • TREATMENT: TRIPLE-NEGATIVE BREAST CANCER
  • Epidemiology: Triple-Negative Breast Cancer

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need. This report addresses the following questions: - Which branded therapies will have the largest commercial potential in the triple-negative breast cancer...

  • Breast Cancer
  • European Union
  • Japan
  • United States
  • TESARO, Inc.
  • Pipeline: HER2-Positive Breast Cancer
  • Treatment: HER2-Positive Breast Cancer

Ibrance’s continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market. This report addresses the following questions: - Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market? - What is the overall market potential for...

  • Breast Cancer
  • European Union
  • United States
  • GlaxoSmithKline plc
  • Roche Group

Europe Breast Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Breast Cancer
  • Europe
  • France
  • Germany
  • Forecast
  • BREAST CANCER
  • Growing incidence of breast cancer

About Breast Biopsy A breast biopsy is a procedure that involves the removal of tissue or fluid from the targeted area. The tissue is examined under a microscope and then tested to determine the presence of breast cancer. A biopsy is the only diagnostic procedure to confirm cancer. About 80% of women who undergo breast biopsy...

  • Biopsy
  • Breast Cancer
  • Magnetic Resonance Imaging
  • C.R. Bard, Inc.
  • Hologic, Inc.

This report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally.

  • Breast Cancer
  • Cancer
  • Therapy
  • World
  • Market Size
  • PROGNOSIS FOR BREAST CANCER
  • AJCC STAGE DEFINITIONS FOR BREAST CANCER

PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities...

  • Breast Cancer
  • Demand
  • Market Size
  • AstraZeneca PLC
  • Pfizer Inc.

US Breast Cancer Lumpectomy Market, Treatment Cost & Opportunity Analysis 2024 ##.

  • Breast Cancer
  • General Medicine And Specialty Medicine
  • Oncology
  • United States

Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals ##.

  • Breast Cancer
  • Cancer
  • Therapy
  • World
  • Market Shares

Breast Cancer Phase ## Clinical Trials, 2016 ##.

  • Breast Cancer
  • France
  • Germany
  • Italy
  • Market Size
  • BREAST CANCER IN EUROPE
  • LUMPECTOMY-TREATMENT OF BREAST CANCER

About Lumpectomy Devices According to a NHS report of July 2015, eight out of ten women are diagnosed with breast cancer in the UK and survive for minimum five years post diagnosis. Lumpectomy, a type of breast-conserving therapy for treating breast cancer, has emerged in the European market, owing to the presence of innovative...

  • Breast Cancer
  • Hospital
  • Europe
  • Cianna Medical, Inc.
  • Hologic, Inc.